Il y a eu 50 transactions d'initiés récentes enregistrées pour Cogent Biosciences, Inc. (COGT), dont 41 achats et 9 ventes. Le total des achats d'initiés s'élève à $64.89M et le total des ventes d'initiés à $139.58M.
Les initiés notables ayant une activité récente comprennent Ferrante Karen Jean, Fairmount Funds Management Llc, Green John L.. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — COGT
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-04-01 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
686 |
$35.24 |
$24.17K |
686 |
| 2026-03-31 |
Fairmount Funds Management Llc |
Director |
Conversion (Vente) |
28,000 |
- |
- |
39,414 |
| 2026-01-22 |
Fairmount Funds Management Llc |
Director |
Vente Informative |
3,500,000 |
$36.40 |
$127.4M |
5,503,418 |
| 2026-01-01 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
643 |
$34.74 |
$22.34K |
643 |
| 2025-12-26 |
Green John L. |
Chief Financial Officer |
Vente Informative |
77,000 |
$38.68 |
$2.98M |
131,834 |
| 2025-12-26 |
Kearns Evan |
Chief Legal Officer |
Vente Informative |
65,000 |
$38.70 |
$2.52M |
109,398 |
| 2025-12-26 |
Sachs Jessica |
Chief Medical Officer |
Vente Informative |
82,642 |
$38.70 |
$3.2M |
133,938 |
| 2025-12-26 |
Robinson John Edward |
Chief Scientific Officer |
Vente Informative |
90,000 |
$38.74 |
$3.49M |
140,002 |
| 2025-12-17 |
Robbins Andrew R |
President and CEO |
Attribution de RSU |
185,000 |
- |
- |
185,000 |
| 2025-12-17 |
Green John L. |
Chief Financial Officer |
Attribution de RSU |
50,000 |
- |
- |
53,841 |
| 2025-12-17 |
Kearns Evan |
Chief Legal Officer |
Attribution de RSU |
40,000 |
- |
- |
40,000 |
| 2025-12-17 |
Sachs Jessica |
Chief Medical Officer |
Attribution de RSU |
50,000 |
- |
- |
51,296 |
| 2025-12-17 |
Robinson John Edward |
Chief Scientific Officer |
Attribution de RSU |
50,000 |
- |
- |
50,000 |
| 2025-12-17 |
Pinnow Cole |
Chief Commercial Officer |
Attribution de RSU |
65,000 |
$39.45 |
$2.56M |
65,000 |
| 2025-10-01 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
1,642 |
$14.13 |
$23.2K |
1,642 |
| 2025-07-10 |
Fairmount Funds Management Llc |
Director |
Achat Informatif |
2,777,777 |
$9.00 |
$25M |
9,003,418 |
| 2025-07-01 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
3,314 |
$7.22 |
$23.93K |
3,314 |
| 2025-06-04 |
Morris Arlene |
Director |
Attribution de RSU |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Harwin Peter Evan |
Director |
Attribution de RSU |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Ros Matthew |
Director |
Attribution de RSU |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Shegog Todd |
Director |
Attribution de RSU |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-06-04 |
Cain Christopher W. |
Director |
Attribution de RSU |
44,700 |
$5.64 |
$252.11K |
44,700 |
| 2025-04-01 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
3,788 |
$5.79 |
$21.93K |
3,788 |
| 2025-01-23 |
Robbins Andrew R |
President and CEO |
Attribution de RSU |
915,000 |
$8.89 |
$8.13M |
915,000 |
| 2025-01-23 |
Green John L. |
Chief Financial Officer |
Attribution de RSU |
270,000 |
$8.89 |
$2.4M |
270,000 |
| 2025-01-23 |
Kearns Evan |
Chief Legal Officer |
Attribution de RSU |
230,000 |
$8.89 |
$2.04M |
230,000 |
| 2025-01-23 |
Sachs Jessica |
Chief Medical Officer |
Attribution de RSU |
270,000 |
$8.89 |
$2.4M |
270,000 |
| 2025-01-23 |
Robinson John Edward |
Chief Scientific Officer |
Attribution de RSU |
270,000 |
$8.89 |
$2.4M |
270,000 |
| 2025-01-23 |
Pinnow Cole |
Chief Commercial Officer |
Attribution de RSU |
240,000 |
$8.89 |
$2.13M |
240,000 |
| 2025-01-14 |
Pinnow Cole |
Chief Commercial Officer |
Achat Informatif |
43,750 |
$7.60 |
$332.41K |
45,848 |
| 2025-01-01 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
2,785 |
$7.80 |
$21.72K |
2,785 |
| 2024-10-01 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
2,034 |
$10.75 |
$21.87K |
2,034 |
| 2024-07-01 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
2,462 |
$8.94 |
$22.01K |
2,462 |
| 2024-06-10 |
Fairmount Funds Management Llc |
Director |
Exercice d'Options (Vente) |
1,500 |
- |
- |
- |
| 2024-06-05 |
Morris Arlene |
Director |
Attribution de RSU |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Harwin Peter Evan |
Director |
Attribution de RSU |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Ros Matthew |
Director |
Attribution de RSU |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Shegog Todd |
Director |
Attribution de RSU |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-06-05 |
Cain Christopher W. |
Director |
Attribution de RSU |
44,700 |
$8.92 |
$398.72K |
44,700 |
| 2024-05-25 |
Pinnow Cole |
Chief Commercial Officer |
Cession |
- |
- |
- |
700 |
| 2024-05-25 |
Pinnow Cole |
Chief Commercial Officer |
Attribution de RSU |
525,000 |
$8.22 |
$4.32M |
525,000 |
| 2024-04-01 |
Ferrante Karen Jean |
Director |
Attribution de RSU |
3,213 |
$6.90 |
$22.17K |
3,213 |
| 2024-03-28 |
Fairmount Funds Management Llc |
Director |
Autre (Vente) |
11,914 |
- |
- |
- |
| 2024-02-16 |
Fairmount Funds Management Llc |
10 Percent Owner |
Attribution de RSU |
1,500 |
- |
- |
1,500 |
| 2024-01-23 |
Robbins Andrew R |
President and CEO |
Attribution de RSU |
1,100,000 |
$4.63 |
$5.09M |
1,100,000 |
| 2024-01-23 |
Green John L. |
Chief Financial Officer |
Attribution de RSU |
300,000 |
$4.63 |
$1.39M |
300,000 |
| 2024-01-23 |
Kearns Evan |
Chief Legal Officer |
Attribution de RSU |
255,000 |
$4.63 |
$1.18M |
255,000 |
| 2024-01-23 |
Sachs Jessica |
Chief Medical Officer |
Attribution de RSU |
300,000 |
$4.63 |
$1.39M |
300,000 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
